UCSF scientist Shaun Coughlin will lead CV research at NIBR, Novo's China GM was promoted to EVP, and Cavion poached Teva exec to head up R&D.
Scientists used stem cells and assisted reproduction to create healthy offspring from genetically infertile mice.
With pressures to fast-track clinical development, the pharmaceutical industry recognizes the value of improving internal clinical data management processes.…
The director of UCSF's Cardiovascular Research Institute—Shaun Coughlin, M.D., Ph.D.—has joined the ranks of senior academics heading to drugmaker…
Alzeca Biosciences raised $11 million to develop its nanoparticle contrast agent, designed for the early detection of Alzheimer’s disease.
The cash tees up Atreca to pick a clinical candidate derived from a platform that has attracted the interest of a who’s who of Big Pharma players.
The collaborators hope to learn about the role Sigma1 plays in disease and assess the activity of Context’s inhibitors of the protein.
U.S. oncology specialist Cancer Genetics will pay $12 million to buy out Australian CRO vivoPharm as it looks to bolster its offerings.
A Genentech-led team has discovered a protein that, when blocked, reverses a signaling pathway that causes neurodegeneration.
Tandem started a pivotal trial of a system that automatically stops insulin delivery when a patient’s blood glucose levels are predicted to fall.
VentureMed Group raised $15 million to support R&D, clinical trials and expand the sales team for its PAD treatment catheter.